IFNA1 and neoplasm: Although we did not observe any differences in the CIBERSORT 22 immune subsets between responders and non-responders (Figure S2), of the 6 Rody metagenes that we applied (MHC-I, MHC-II, HCK, LCK, IFN, and STAT1), C+K+ tumours expressed higher levels of the MHC-II metagene (p = 0.0696) than other tumours (Fig. 1d).